APA (7th ed.) Citation

B, H., S, M., S, S., N, P., K, T., K, V. E., . . . S, A. (2024). Real-life data of luspatercept in lower-risk myelodysplastic syndromes advocate new research objectives. EJHaem, 5(5), 1096. https://doi.org/10.1002/jha2.1027

Chicago Style (17th ed.) Citation

B, Heyrman, et al. "Real-life Data of Luspatercept in Lower-risk Myelodysplastic Syndromes Advocate New Research Objectives." EJHaem 5, no. 5 (2024): 1096. https://doi.org/10.1002/jha2.1027.

MLA (9th ed.) Citation

B, Heyrman, et al. "Real-life Data of Luspatercept in Lower-risk Myelodysplastic Syndromes Advocate New Research Objectives." EJHaem, vol. 5, no. 5, 2024, p. 1096, https://doi.org/10.1002/jha2.1027.